ZA200908303B - A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation - Google Patents

A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation

Info

Publication number
ZA200908303B
ZA200908303B ZA2009/08303A ZA200908303A ZA200908303B ZA 200908303 B ZA200908303 B ZA 200908303B ZA 2009/08303 A ZA2009/08303 A ZA 2009/08303A ZA 200908303 A ZA200908303 A ZA 200908303A ZA 200908303 B ZA200908303 B ZA 200908303B
Authority
ZA
South Africa
Prior art keywords
disorders
treatment
protein aggregation
cyclohexane polyalcohol
polyalcohol formulation
Prior art date
Application number
ZA2009/08303A
Other languages
English (en)
Inventor
Joanne Mclaurin
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc
Joanne Mclaurin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc, Joanne Mclaurin filed Critical Waratah Pharmaceuticals Inc
Publication of ZA200908303B publication Critical patent/ZA200908303B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2009/08303A 2006-03-09 2009-11-24 A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation ZA200908303B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78052606P 2006-03-09 2006-03-09
US81986406P 2006-07-11 2006-07-11
US89766707P 2007-01-26 2007-01-26

Publications (1)

Publication Number Publication Date
ZA200908303B true ZA200908303B (en) 2012-08-29

Family

ID=38474578

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/08303A ZA200908303B (en) 2006-03-09 2009-11-24 A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation

Country Status (14)

Country Link
US (1) US20100113613A1 (enExample)
EP (1) EP1996175A4 (enExample)
JP (1) JP2009529502A (enExample)
KR (1) KR20090026247A (enExample)
CN (1) CN103054837A (enExample)
AU (1) AU2007222864A1 (enExample)
BR (1) BRPI0708725A2 (enExample)
CA (1) CA2644804A1 (enExample)
EA (1) EA200801967A1 (enExample)
IL (1) IL193970A0 (enExample)
MX (1) MX2008011553A (enExample)
NZ (1) NZ571181A (enExample)
WO (1) WO2007101353A1 (enExample)
ZA (1) ZA200908303B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
CA2670405A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and related neurodegenerative diseases
DE102007030695A1 (de) * 2007-07-01 2009-01-08 Sciconcept Gmbh Co-Kristalle aus Harnstoff mit Amid- und/oder Harnstoffderivaten
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2714050A1 (en) * 2011-06-03 2014-04-09 Elan Pharmaceuticals, Inc. Scyllo-inositol for the treatment of behavioral and psychiatric disorders
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
EP2964249A1 (en) * 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
KR20190044647A (ko) 2016-08-31 2019-04-30 더 제너럴 하스피탈 코포레이션 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
WO2020123449A1 (en) 2018-12-10 2020-06-18 The General Hospital Corporation Cromolyn esters and uses thereof
EP4132507A4 (en) 2020-04-06 2024-05-15 The General Hospital Corporation METHODS FOR TREATING CORONAVIRUS-INDUCED INFLAMMATORY CONDITIONS

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4758430A (en) * 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5217959A (en) * 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
US5112814A (en) * 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
CA2146353C (en) * 1992-10-05 2007-04-17 Tomas Hudlicky Syntheses of d-chiro-3-inosose and (+)-d-chiro-inositol
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
DE69333071T2 (de) * 1993-04-05 2004-05-06 Aveve N.V. Phytate-Hydrolyse und enzymatische Zusammensetzung für die Hydrolyse von Phytat
DE69416594T2 (de) * 1993-08-11 1999-09-23 Hokko Chemical Industry Co. Ltd., Tokio/Tokyo Verfahren zur herstellung von d-chiro inositol
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6232486B1 (en) * 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6818430B1 (en) * 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6329256B1 (en) * 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
CZ20021346A3 (cs) * 1999-10-18 2003-06-18 Muscletech Research And Development Inc. Potravinový doplněk pro růst svalové hmoty a síly
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US8034803B2 (en) * 2001-02-06 2011-10-11 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
US7060695B2 (en) * 2001-02-06 2006-06-13 Qlt, Inc. Method to prevent vision loss
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP4526485B2 (ja) * 2003-10-14 2010-08-18 北興化学工業株式会社 シロ−イノシトールの製造方法
MX2007005870A (es) * 2004-11-17 2007-10-10 Joanne Mclauring Composiciones que comprenden derivados de escilo-inositol y metodos para tratar trastornos de agregacion de proteinas.

Also Published As

Publication number Publication date
MX2008011553A (es) 2008-12-09
AU2007222864A1 (en) 2007-09-13
JP2009529502A (ja) 2009-08-20
KR20090026247A (ko) 2009-03-12
BRPI0708725A2 (pt) 2011-06-07
CN103054837A (zh) 2013-04-24
CA2644804A1 (en) 2007-09-13
NZ571181A (en) 2011-12-22
IL193970A0 (en) 2009-08-03
EP1996175A4 (en) 2009-06-10
EA200801967A1 (ru) 2009-04-28
US20100113613A1 (en) 2010-05-06
EP1996175A1 (en) 2008-12-03
AU2007222864A8 (en) 2010-06-10
WO2007101353A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
ZA200908303B (en) A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
EP2010187A4 (en) CONNECTIONS FOR DISEASES AND FUNCTIONAL DISORDERS
ZA200809528B (en) Treatment for depressive disorders
IL213341A0 (en) Dipeptide linked medicinal agents
IL212404A0 (en) Compounds for treating ophthalmic diseases and disorders
PT2004155T (pt) Inibidores de agregação proteica
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
IL209267A (en) Combinations containing methotrexate and dhodh inhibitors and their use in the preparation of the drug
ZA200809527B (en) Treatment for depressive disorders
IL193747A0 (en) New therapeutic combinations for the treatment of depression
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
PL2341047T3 (pl) Pochodna cykloheksanowa i jej farmaceutyczne zastosowanie
EP1993523A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
GB0914423D0 (en) Treatment of protein aggregation diseases
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
ZA200807993B (en) A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
IL212719A0 (en) Gold nanoparticles coated with polyelectrolytes and use thereof as medicament for the treatment of neurodegenerative diseases caused by protein aggregates
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
ZA200900556B (en) Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders
GB0616122D0 (en) Formulation for treatment of skin disorders
HK1144087A (en) Compounds for treating ophthalmic diseases and disorders
HK1160633A (en) Compounds for treating ophthalmic diseases and disorders